Cannabis Report
Home > Boards > US Listed > Medical - Healthcare >

Xenetic Biosciences Inc. (XBIO)

Add XBIO Price Alert      Hide Sticky   Hide Intro
Moderator: Chappy86, l2 hunter
Search This Board: 
Last Post: 9/19/2018 9:47:34 AM - Followers: 22 - Board type: Free - Posts Today: 0

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Xenetic's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Further, Xenetic's proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The Company has ongoing business development activities to explore partnerships utilizing its PolyXen delivery platform.

FLOAT                                        2.29M
% Held by Insiders 1 75.11%
% Held by Institutions 1 0.39%

As of 14 June 2018


We incorporate our patented and proprietary technologies into a number of drug candidates currently under development either in-house or with biotechnology and pharmaceutical collaborators in order to create what we believe will be the next-generation of biologic drugs and therapeutics. While we primarily focus on researching and developing orphan oncology drugs, we also have significant ownership or other economic interests in drugs being developed by our collaborators.


PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin and recombinant Factor VIII (rFVIII).

XBIO-101 (sodium cridanimod)

XBIO-101 is a small-molecule immunomodulator and interferon inducer which, in preliminary studies, has been shown to increase progesterone receptor (PrR) expression in endometrial tissue. The Company has exclusive rights to develop and commercialize XBIO-101 worldwide, except for specified countries in the Commonwealth of Independent States, including Russia. XBIO-101 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of progesterone receptor negative (PrR-) endometrial cancer in conjunction with progesterone therapy. XBIO-101 is currently being studied in an ongoing Phase 2 clinical trial. Patient enrollment for the Phase 2 trial commenced in June 2017.

  • The primary objective of the open-label, multi-center, single-arm, two-period Phase 2 study is to assess the antitumor activity of XBIO-101 in conjunction with progestin therapy as measured by Overall Disease Control Rate in women with recurrent or persistent endometrial carcinoma not amenable to surgical treatment or radiotherapy who have either failed progestin monotherapy or who have been identified as PrR-. Secondary objectives include assessments of efficacy and safety/tolerability
    The study is expected to enroll a total of 72 women with recurrent or persistent endometrial cancer not amenable to surgical treatment or radiotherapy but suitable to be treated with progestins. All subjects determined to be PrR- at screening, as well as those subjects who experience disease progression after at least 4 weeks of progestin monotherapy, will receive XBIO-101 in combination with continued progestin treatment. Subjects will receive treatment until disease progression as defined according to RECIST 1.1 criteria.


Key Executives

Name Title Pay Exercised Year Born
Mr. Jeffrey F. Eisenberg CEO, Pres & Director 44.81k N/A 1966
Mr. James F. Parslow CFO, COO & Corp. Sec. N/A N/A 1965
Dr. Curtis A. Lockshin Chief Scientific Officer N/A N/A 1960

Transfer Agent


Shareholders of Record   424
Latest 10Q

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1335   Waiting 4 news toybaby 09/19/18 09:47:33 AM
#1334   hopefully they won't toybaby 09/13/18 09:55:19 AM
#1333   Never know what will happen with these. As Chappy86 09/12/18 05:44:15 PM
#1332   Yes but my average is 3.80 so toybaby 09/12/18 05:38:42 PM
#1331   There's not much downside from here. Present price Chappy86 09/12/18 04:28:29 PM
#1330   Ha ha U got me ~~~ toybaby 09/12/18 03:49:03 PM
#1329   I wish I knew but you can't win Chappy86 09/12/18 03:34:35 PM
#1328   Any idea as to when we will cash toybaby 09/12/18 03:15:51 PM
#1327   Picking up cheap ones Chappy86 09/12/18 09:31:36 AM
#1326   Very wise...thank you. Chappy86 09/08/18 07:10:52 PM
#1325   The Moral ISSSSS````U can't win toybaby 09/08/18 04:49:35 PM
#1324   I told a buddy of mine to buy Rocketstockpix 09/08/18 02:27:26 PM
#1323   forget watching. buy and pray for the best.. Rocketstockpix 09/08/18 02:22:17 PM
#1322   Absolutely agree. Watch it and others daily. Chappy86 09/08/18 02:18:30 PM
#1321   the problem is you have to be in Rocketstockpix 09/08/18 02:17:00 PM
#1320   Sure don't know but am watching for a Chappy86 09/08/18 02:13:21 PM
#1319   How low do we go? Rocketstockpix 09/08/18 10:03:49 AM
#1318   nice end of day surprise !! toybaby 08/30/18 04:04:37 PM
#1317   No sir, if you remember there was none Chappy86 08/27/18 04:12:52 PM
#1316   Is there a date 4 Q3 toybaby 08/27/18 03:38:11 PM
#1315   We should be about due for an upswing Chappy86 08/23/18 02:44:25 PM
#1314   Not much longer G L to All toybaby 08/23/18 11:45:08 AM
#1313   I love how this stock moves on thin air. Cdub420 08/21/18 12:34:21 PM
#1312   will this be the end of September? or later toybaby 08/21/18 09:06:08 AM
#1311   Agreed...other than an occasional burst but lower price Chappy86 08/21/18 08:16:26 AM
#1310   Nothing can be expected until Q3, the stock Kabuli 08/20/18 06:32:51 PM
#1309   can we expect the Company to put out toybaby 08/20/18 06:29:27 PM
#1308   10-Q page 13 indicates: Our Phase 2 trial Kabuli 08/20/18 04:36:06 PM
#1307   Xbio seems losing steam. RisingProfit 08/20/18 03:26:46 PM
#1306   Agreed bobl17211 08/20/18 09:45:00 AM
#1305   Am willing to wait !! toybaby 08/20/18 06:21:34 AM
#1304   10-Q page 13 indicates: Our Phase 2 trial Kabuli 08/20/18 03:03:35 AM
#1303   Sure hope so...we need it bobl17211 08/19/18 09:49:28 PM
#1302   News next week? toybaby 08/19/18 02:24:14 PM
#1301   GM $XBIO. Have a great day. Chappy86 08/17/18 08:01:37 AM
#1300   G M and have excellent weekend! toybaby 08/17/18 07:20:32 AM
#1299   Xbio keeps giving. Kabuli 08/16/18 04:13:23 PM
#1298   You're right this could explode w/o warning. It's Chappy86 08/16/18 02:15:04 PM
#1297   looks like the accumulation is done. ready for l2 hunter 08/16/18 12:20:04 PM
#1296   5 minute chart shows a parabolic curve forming. Hmmm Chappy86 08/16/18 12:19:27 PM
#1295   Nice little pop! Chappy86 08/16/18 12:14:13 PM
#1294   You are right and there will drops and Chappy86 08/16/18 09:14:49 AM
#1293   things looking Better toybaby 08/16/18 09:10:02 AM
#1292   GM $XBIO Chappy86 08/16/18 09:09:46 AM
#1291   Unfortunately it will go down, until news comes Kabuli 08/15/18 05:09:46 PM
#1290   Time to cover short mclaxer5155 08/15/18 03:17:55 PM
#1289   Short covering? bobl17211 08/15/18 12:14:06 PM
#1288   Whale just bought 10000 shares get ready for reversal mclaxer5155 08/15/18 11:57:13 AM
#1287   Very quiet here. Chappy86 08/15/18 11:40:28 AM
#1286   GM $XBIO Chappy86 08/15/18 08:09:29 AM